Occurrence of leukaemia following gene therapy of X-linked SCID (original) (raw)

• Kohn, D. B. Gene therapy for genetic and haematological disorders and immunodeficiency. J. Int. Med. 249, 379–390 (2001).
  Article CAS Google Scholar
• Vijaya, S. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 60, 683–692 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Rohdewohld, H. et al. Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J. Virol. 61, 336–343 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521–529 (2002). A paper that catalogued more than 500 independent genomic integration sites of HIV in human cells. A modest preference was seen for integration into gene-rich regions that were actively transcribed.
  Article CAS PubMed Google Scholar
• Nakai, H. et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nature Genet. 1 Jun 2003 (doi:10.1038/ng1179).
• Kotin, R. M. et al. Site specific integration by adeno-associated virus. Proc. Natl Acad. Sci. USA. 87, 2211–2215 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Strayer, D. S. et al. Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Mol. Ther. (in the press).
• Miller, A. D. in Retroviruses (eds Coffin, F. M., Hughes, S. H. & Varmus, H. E.) 437–474 (Cold Spring Harbor Laboratory Press, New York, 1997).
  Google Scholar
• Baum, C., Ostertag, W., Stocking, C. & von Laber, D. in Gene Therapy of Cancer (eds Lattime, E. C. & Gerson, S. L.) 3–30 (Academic Press, Missouri, USA, 2002).
  Book Google Scholar
• Heim, D. A. & Dunbar, C. E. Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency. Immunol. Rev. 178, 29–38 (2000).
  Article CAS PubMed Google Scholar
• Halene, S. & Kohn, D. B. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum. Gene Ther. 11, 1259–1267 (2000).
  Article CAS PubMed Google Scholar
• Sadelain, M. et al. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. Curr. Opin. Hematol. 7, 364–377 (2000).
  Article CAS PubMed Google Scholar
• Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672 (2000). The first report on the effects of gene therapy in two patients with X-linked SCID subjects. This paper marks the milestone of the first 'cure' of a disease by gene therapy.
  Article CAS PubMed Google Scholar
• Hacein-Bey-Abina, S. et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185–1193 (2002). A second report with longer follow-up of the first two subjects reported in reference 7, with three additional subjects reported. Restoration of immunity was seen in four of five subjects. Two of these subjects subsequently developed T-cell leukaemia.
  Article CAS PubMed Google Scholar
• Weinberg, K. I. & Kohn, D. B. Gene therapy for congenital lymphoid immunodeficiency diseases. Semin. Hematol. 35, 354–366 (1998).
  CAS PubMed Google Scholar
• Antoine, C. S. et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet 361, 553–560 (2003).
  Article PubMed Google Scholar
• Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413 (2002). The first report of immune restoration in two patients with ADA-deficient SCID. Unlike all previous gene-therapy studies for this form of SCID, these subjects were not treated with PEG-ADA enzyme-replacement therapy, which is believed to reduce the selective advantage of the gene-corrected cells. Additionally, these subjects received bone-marrow cytoreduction with a moderate dosage of the chemotherapeutic agent busulphan, which could promote engraftment of the gentically modified cells.
  Article CAS PubMed Google Scholar
• Marshall, E. Gene therapy. Second child in French trial is found to have leukemia. Science 299, 320 (2003).
  Article CAS PubMed Google Scholar
• Wu, X. & Pandolfi, P. P. Mouse models for multistep tumorigenesis. Trends Cell Biol. 11, S2–S9 (2001).
  Article CAS PubMed Google Scholar
• Rosenberg, N. et al. in Retroviruses (eds Coffin, A. M., Hughes, S. H. & Varmus, H. E.) 475–585 (Cold Spring Harbor Laboratory Press, New York, 1997).
  Google Scholar
• Suzuki, T. et al. New genes involved in cancer identified by retroviral tagging. Nature Genet. 32, 166–174 (2002). In this study (and also references 22 and 23), researchers sequenced retroviral insertional sites in the mouse genome to examine cellular oncogenes that are involved in transformation. Multiple genes in specific signalling pathways were shown to promote transformation.
  Article CAS PubMed Google Scholar
• Mikkers, H., J. et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nature Genet. 32, 153–159 (2002).
  Article CAS PubMed Google Scholar
• Joosten, M. et al. Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites. Oncogene 21, 7247–7255 (2002).
  Article CAS PubMed Google Scholar
• Morishita, K. et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell line. Cell 54, 831–840 (1988).
  Article CAS PubMed Google Scholar
• Kohn, D. B. et al. Report of the ad hoc sub-committee of the American Society of Gene Therapy on clinical trials conducted using retroviral-mediated gene transfer to hematopoietic stem cells. Mol. Ther. (in the press).
• Li, Z. et al. Murine leukemia induced by retroviral gene marking. Science 296, 497 (2002). The first reported observation of insertional oncogenesis by a replication-incompetent retroviral vector. The retroviral vector was inserted near the Evi1 locus — a gene that is associated with acute myeloid leukaemia.
  Article CAS PubMed Google Scholar
• Nucifora, G. in Transcription Factors: Normal and Malignant Development of Blood Cells (eds Ravid, K. & Licht, J. D.) 393–404 (Wiley-Liss, New Jersey, USA 2001).
  Google Scholar
• Osada, H. et al. Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc. Natl Acad. Sci. USA 92, 9585–9589 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Rabbitts, T. H. et al. The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development. Cancer Res. 59 (7 Suppl), 1794s–1798s (1999).
  CAS PubMed Google Scholar
• Royer-Pokora, B., Loos, U. & Ludwig, W. D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6, 1887–1893 (1991).
  CAS PubMed Google Scholar
• Larson, R. C. et al. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 11, 853–862 (1995).
  CAS PubMed Google Scholar
• Neale, G. A, Rehg, J. E. & Goorha, R. M. Ectopic expression of rhombotin-2 causes selective expansion of CD4−CD8− lymphocytes in the thymus and T-cell tumors in transgeneic mice. Blood 86, 3060–3071 (1995).
  Article CAS PubMed Google Scholar
• Rabbits, T. H. Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene 20, 5763–5777 (2001).
  Article CAS Google Scholar
• Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75–87 (2002).
  Article CAS PubMed Google Scholar
• Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T(−)B(+)NK(+) severe combined immunodeficiency. Nature Genet. 20, 394–397 (1998).
  Article CAS PubMed Google Scholar
• Schluns, K. S., Kieper, W. C., Jameson, S. C. & Lefrancois, L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nature Immunol. 1, 426–432 (2000).
  Article CAS Google Scholar
• Schluns, K. S. & Lefrancois, L. Cytokine control of memory T-cell development and survival. Nature Rev. Immunol. 3, 269–279 (2003).
  Article CAS Google Scholar
• Valenzona, H. O. Prelymphomatous B cell hyperplasia in the bone marrow of interleukin-7 transgenic mice: precursor B cell dynamics, microenvironmental organization and osteolysis. Exp. Hematol. 24, 1521–1529 (1996).
  CAS PubMed Google Scholar
• Fehniger, T. A. et al. Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol. Dis. 27, 223–230 (2001).
  Article CAS PubMed Google Scholar
• Renauld, J. C. et al. Thymic lymphomas in interleukin 9 transgenic mice. Oncogene 9, 1327–1332 (1994).
  CAS PubMed Google Scholar
• Lange, K. et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 22, 517–527 (2003).
  Article CAS PubMed Google Scholar
• Fehniger, T. A. & Caligiuri, M. A. Interleukin-15: biology and relevance to human disease. Blood 97, 14–32 (2001).
  Article CAS PubMed Google Scholar
• Barata, J. T., Cardoso, A. A., Nadler, L. M. & Boussiotos, V. A. Interleukin-7 promotes survival and cell cycle progression of T cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 98, 1524–1531 (2001).
  Article CAS PubMed Google Scholar
• Bolotin, E. et al. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 23, 783–788 (1999).
  Article CAS PubMed Google Scholar
• Sadelain, M. & Riviere, I. Sturm und drang over suicidal lymphocytes. Mol. Ther. 5, 655–657 (2002).
  Article CAS PubMed Google Scholar
• Mavilio, F. et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83, 1988–1997 (1994).
  Article CAS PubMed Google Scholar
• Bonini, C. et al. Safety of retroviral gene marking with a truncated NGF receptor. Nature Med. 9, 367–368 (2003).
  Article CAS PubMed Google Scholar
• Dunn, G. P. et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002).
  Article CAS Google Scholar
• Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).
  CAS PubMed Google Scholar
• O'Reilly, R. J. et al. Biology and adoptive cell therapy of EBV-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol. Rev. 157, 195–216 (1997).
  Article CAS PubMed Google Scholar
• Okano, M. & Gross, T. G. A review of Epstein–Barr virus infection in patients with immunodeficiency disorders. Am. J. Med. Sci. 319, 392–396 (2000).
  Article CAS PubMed Google Scholar
• Smyth, M. J., Hayakawa, Y., Takeda, K. & Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Rev. Cancer 2, 850–861 (2002).
  Article CAS Google Scholar
• Soudais, C. et al. Stable and functional lymphoid of common cytokine reception chain deficient mice by retroviral-mediated gene transfer. Blood 95, 3071–3077 (2000).
  Article CAS PubMed Google Scholar
• Valk, P. J. A rapid RT-PCR based method to isolate complementary DNA fragments flanking retrovirus integration sites. Nucleic Acids Res. 25, 4419–4421 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Schmidt, M. et al. Detection and direct genomic sequencing of multiple rate unknown flanking DNA in highly complex samples. Hum. Gene Ther. 12, 743–749 (2001). Description of the LAM-PCR technique that was used by Christoph von Kalle and colleagues to uncover the LMO2 integration sites in the two leukaemia patients.
  Article CAS PubMed Google Scholar
• Donahue, R. E. et al. Helper virus induced t cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125–1135 (1992).
  Article CAS PubMed Google Scholar
• Yu, S. F. et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl Acad. Sci. USA 83, 3194–3198 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Ismail, S. I., Rohll, J. B., Kingsman, S. M., Kingsman, A. J. & Uden, M. Use of intron-disrupted polyadenylation sites to enhance expression and safety of retroviral vectors. J. Virol. 75, 199–204 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Zaiss, A. K. et al. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J. Virol. 76, 7209–7219 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Sadelain, M. Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for stem cell-based gene therapy. J. Gene Med. 4, 113–121 (2002).
  Article PubMed Google Scholar
• Rivella, S. & Sadelain, M. Therapeutic globin gene delivery using lentiviral vectors. Curr. Opin. Mol. Ther. 4, 505–514 (2002).
  CAS PubMed Google Scholar
• May, C. et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406, 82–86 (2000). Shows that lentiviral vector-mediated erythroid-specific expression of a globin gene can be used to treat haemoglobinopathies. This was an elusive goal for investigators who were trying the same approach using retroviral vectors, due to instability conferred by the necessary globin genomic regulatory sequences.
  Article CAS PubMed Google Scholar
• Baron, U. Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res. 25, 2723–2729 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Gerasimova, T. I. & Corces, V. G. Chromatin insulators and boundaries: effects on transcription and nuclear organization. Annu. Rev. Genet. 35, 193–208 (2001).
  Article CAS PubMed Google Scholar
• West, A. G., Gazner, M. & Felsenfold, G. Insulators: many functions, many mechanisms. Genes Dev. 16, 271–288 (2002).
  Article CAS PubMed Google Scholar
• Rivella, S. et al. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Virol. 74, 4679–4687 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Emery, D. W. et al. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl Acad. Sci. USA 97, 9150–9155 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Cohen, J. L. et al. Suicide gene-mediated modulation of graft-versus-host disease. Leuk. Lymph. 34, 473–480 (1999).
  Article CAS Google Scholar
• Boeke, J. D. et al. Yeast retrotransposons: finding a nice quiet neighborhood. Cell 93, 1087–1089 (1998).
  Article CAS PubMed Google Scholar
• Bushman, F. Targeting retroviral integration? Mol. Ther. 6, 570–571 (2002).
  Article CAS PubMed Google Scholar
• Buckley, R. H. et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J. Pediatr. 130, 378–387 (1997).
  Article CAS PubMed Google Scholar
• Fischer, A. et al. Naturally occurring primary deficiencies of the immune system. Annu. Rev. Immunol. 15, 93–124 (1997).
  Article CAS PubMed Google Scholar
• Leonard, W. J. The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med. 47, 229–239 (1996).
  Article CAS PubMed Google Scholar
• Noguchi, M. et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147–157 (1993).
  Article CAS PubMed Google Scholar
• de Saint Basile, G. et al. Close linkage of the locus for X chromosome-linked severe combined immunodeficiency to polymorphic DNA markers in Xq11–q13. Proc. Natl Acad. Sci. USA 84, 7576–7579 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Puck, J. M., Nussbaum, R. L., Smead, D. L. & Conley, M. E. X-linked severe combined immunodeficiency: localization within the region Xq13.1-q21.1 by linkage and deletion analysis. Am. J. Hum. Genet. 44, 724–730 (1989).
  CAS PubMed PubMed Central Google Scholar
• Giri, J. et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J. Immunol. 153, 5802–5809 (1994).
  CAS PubMed Google Scholar
• Kondo, M. et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 262, 1874–1877 (1993).
  Article CAS PubMed Google Scholar
• Russell, S. M. et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science 262, 1880–1883 (1993).
  Article CAS PubMed Google Scholar
• Noguchi, M. et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 262, 1877–1880 (1993).
  Article CAS PubMed Google Scholar
• Kondo, M. et al. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 263, 1453–1454 (1994).
  Article CAS PubMed Google Scholar
• Russell, S. M. et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266, 1042–1045 (1994).
  Article CAS PubMed Google Scholar
• Kimura, Y. et al. Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int. Immunol. 7, 115–120 (1995).
  Article CAS PubMed Google Scholar
• Asao, H. et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167, 1–5 (2001).
  Article CAS PubMed Google Scholar
• Leonard, W. J. Cytokines and immunodeficiency diseases. Nature Rev. Immunol. 1, 200–208 (2001).
  Article CAS Google Scholar
• Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771–780 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669–676 (1998).
  Article CAS PubMed Google Scholar
• Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65–68 (1995).
  Article CAS PubMed Google Scholar
• Russell, S. M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797–800 (1995).
  Article CAS PubMed Google Scholar
• Coffin, J. M. in Fields Virology (eds Fields, B., Knipe, N., Howley, D. M.) 1767–1848 (Lippincott-Raven, USA, 1996).
  Google Scholar
• Bishop, J. M. Molecular themes in oncogenesis. Cell 64, 235–248 (1991).
  Article CAS PubMed Google Scholar
• Haran–Ghera, N. Potential leukemic cells among bone marrow cells of young AKR/J mice. Proc. Natl Acad. Sci. USA, 77, 2923–2926 (1980).
  Article PubMed PubMed Central Google Scholar
• Asjo, B. et al. Influence of genotype and the organ of origin on the subtype of T-cell in Moloney lymphomas induced by transfer of preleukemic cells from athymic and thymus-bearing mice. Cancer Res. 45, 1040–1045 (1985).
  CAS PubMed Google Scholar
• Fan, H., Brightman, B. K., Davis, B. R. & Li, Q. X. in Viruses that Affect the Immune System (ed. Fan, H.Y. et al.) 155–174 (American Society for Microbiology, Washington DC, 1991).
  Google Scholar
• Lazo, P. A., Lee, J. S. & Tsichlis, P. N. Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in rat T-cell lymphomas. Proc. Natl Acad. Sci. USA 87, 170–173 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Bartholomew, C. & Ihle, J. N. Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter. Mol. Cell. Biol. 11, 1820–1828 (1991).
  CAS PubMed PubMed Central Google Scholar
• Corcoran, L. M., Adams, J. M., Dunn, A. R. & Cory, S. Murine T lymphomas in which the cellular myc oncogene has been activated by retroviral insertion. Cell 37, 113–122 (1984).
  Article CAS PubMed Google Scholar
• Selten, G., Cuypers, H. T. & Berns, A. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J. 4, 1793–1798 (1985).
  Article CAS PubMed PubMed Central Google Scholar